Full year performance to further exceed market consensus

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that strong trading in October, combined with expected orders for the remainder of the year, will result in full year performance ahead of market expectations, which have already been revised upwards several times this year.

A significantly improved trading in the core business in the final quarter, along with continued orders for the PrimeStore MTM COVID-19 sample collection device underpins the Board's confidence of a strong full year performance.

EKF now expects to deliver Group revenues and adjusted EBITDA for the year ending 31 December 2020 comfortably ahead of market consensus, with expectations currently set at £60m for revenues and adjusted EBITDA of £23m.

The persons responsible for arranging the release of this Announcement on behalf of the Company are Julian Baines, CEO, and Richard Evans, FD and COO respectively.

Enquiries:

EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD and COO

www.ekfdiagnostics.com
Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker)

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)
Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303

Attachments

  • Original document
  • Permalink

Disclaimer

EKF Diagnostics Holdings plc published this content on 09 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 November 2020 16:39:01 UTC